Calls for papers
-
Boehringer Ingelheim said recently that it has completed a €105 million expansion of its facilities in Dortmund and Ingelheim, Germany to increase manufacturing capacity for its Respimat soft mist inhaler. The company said that the… Read more . . .
-
Neurelis, which submitted an NDA for its Valtoco diazepam nasal spray in September 2018, has announced the appointments of a number of senior management personnel in anticipation of a launch. The appointments announced took place… Read more . . .
-
Novus Therapeutics said that two Phase 1 trials of its OP0201 intranasal MDI, which is in development for otitis media, both met their primary endpoints. In one of the studies, healthy adults received either a… Read more . . .
-
The FDA has announced the final approval of Teva’s ANDA for a generic naloxone hydrochloride nasal spray. According to the announcement, the agency tentatively approved the ANDA in June 2018. Opiant Pharmaceutical’s Narcan nasal spray… Read more . . .
-
Akorn announced that the FDA has approved an ANDA for fluticasone propionate nasal spray submitted by Hi Tech Pharmacal, which was acquired by Akorn in 2014. The nasal spray is a generic of GSK’s Flonase,… Read more . . .
-
What is dynamic powder testing and why is it valuable for DPI development? Read more . . .
-
According to Hovione Technology, the company has acquired global development and commercialization rights to the Papillon multi-use dry powder inhaler from its inventor, Klaus-Dieter Beller. The blister-based DPI is reusable and formed from a single… Read more . . .
-
Following Pulmatrix’s recent successful public offering, Pulmatrix and Cipla subsidiary Cipla Technologies (Cip Tec) have entered into a definitive agreement in which Cipla will acquire rights to the Pulmazole itraconazole DPI for the treatment of… Read more . . .
-
Cipla Limited has announced the launch of its Niveoli extra-fine particle beclomethasone/formoterol fumarate MDI for the treatment of asthma and COPD in adults in India. Cipla India Business Head Nikhil Chopra commented, “Cipla is pleased… Read more . . .
-
Insmed Incorporated said that the U.S. Patent and Trademark Office (USPTO) has issued US patent No. 10,251,900, titled “Methods for treating pulmonary non-tuberculous mycobacterial infections,” which is the 10th US patent covering the use of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland